These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25608927)

  • 1. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 3. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 4. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 6. Colorectal cancer: to stack or sequence therapy?
    Azvolinsky A
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957442
    [No Abstract]   [Full Text] [Related]  

  • 7. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 8. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
    Muro K
    Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 10. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 11. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, chemotherapy and KRAS status in mCRC.
    Gill S; Goldberg RM
    Nat Rev Clin Oncol; 2009 Jul; 6(7):379-80. PubMed ID: 19561631
    [No Abstract]   [Full Text] [Related]  

  • 14. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 15. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 16. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C; George T; Yothers G
    J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
    [No Abstract]   [Full Text] [Related]  

  • 18. [Improving longevity in advanced intestinal cancer].
    Schmoll HJ
    Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting regimens in advanced colon cancer.
    Diasio RB
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-19-24. PubMed ID: 23570094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.